Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a ...
To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...
Zacks.com on MSN8d
Novartis Reports Updated Positive Data From Phase III SMA ProgramNVS reports new safety and efficacy data from the phase III program for its investigational OAV101 IT gene therapy for SMA ...
Intrathecal onasemnogene abeparvovec (OAV101 IT), an investigational, one-time gene replacement therapy, demonstrated a ...
Swiss pharma major Novartis (NOVN: VX) has announced positive results from its Phase III STEER study, evaluating the efficacy ...
Novartis (NVS) announced positive safety and efficacy results from the Phase III program for investigational intrathecal onasemnogene ...
Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...
Novartis announces positive data from phase III study of intrathecal onasemnogene abeparvovec in broad patient population with SMA: Basel Friday, March 21, 2025, 11:00 Hrs [IST] N ...
GlobalData on MSN8d
Novartis reports Phase III efficacy and safety outcomes of SMA treatmentNovartis has reported positive efficacy and safety outcomes from its Phase III clinical programme for OAV101 IT (onasemnogene ...
Novartis NVS reported promising new safety and efficacy results from its phase III studies of investigational intrathecal onasemnogene abeparvovec (OAV101 IT) in a broad group of patients aged 2 ...
After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback